Harpoon Therapeutics announces first patients with SCLC dosed in HPN328 trial

Harpoon Therapeutics announced dosing of the first patients with small cell lung cancer, SCLC, in an ongoing Phase 1/2 trial of HPN328, a DLL3 targeting TriTAC, in combination with atezolizumab. Harpoon previously entered a Master Clinical Supply Agreement with F. Hoffmann-La Roche for the supply of atezolizumab. “Dosing the first patients in these combination cohorts for HPN328 with atezolizumab in patients with SCLC marks a significant milestone for this clinical program,” said Luke Walker, M.D., Chief Medical Officer for Harpoon Therapeutics. “Building on the strength of our Phase 1 data, we remain committed to realizing the full potential of HPN328 as an important treatment option for patients with SCLC and other neuroendocrine tumors across early and late lines of therapy.”